Lupin’s Q1 Profit Soars 16% Past Forecasts; Shares Rally

Lupin Pharmaceuticals reported a consolidated net profit of Rs 1,415 crore for the June quarter, marking a 16% year-on-year increase. This robust performance significantly exceeded Bloomberg and Street estimates, driving a surge in the company’s share price.

• Consolidated Net Profit: Rs 1,415 crore (up 16% YoY)
• Total Revenue: Rs 8,277 crore (up 32% YoY)
• EBITDA: Rs 2,463 crore (surged 50%)
• Operating Margin: 29.8% (expanded 360 basis points)
• US Business Revenue: $366 million (up 30% YoY)
• India Revenues: up 14%

Following the announcement, Macquarie reaffirmed its ‘Outperform’ rating for the drugmaker, setting a target price of Rs 2,750. The brokerage described the quarter as a “solid all-round beat,” noting better-than-anticipated operating results and strong execution.

Operational Excellence and Market Gains

Lupin’s US business emerged as a crucial growth driver, with revenue climbing 30% year-on-year to $366 million. This growth occurred despite mid-single-digit pricing pressure on certain products within the market.

• Continued market share gains in key therapeutic areas.
• Three new product launches during the June quarter.
• Strong demand in chronic therapies and anti-diabetes products in India.
• Double-digit growth across Europe, Latin America, and other emerging markets.

Macquarie concluded that Lupin has commenced FY27 on a strong note, supported by earnings that surpassed expectations, enhanced margins, and a promising product pipeline. Investors are now keenly awaiting management’s commentary during the earnings call for insights into upcoming launches, regulatory filings, and the company’s ability to sustain margin momentum throughout the financial year.